Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SANUWAVE HealthSNWV -2.36%29 Debt-to-Equity is 7.43 as of Jun. 2026. GuruFocus rates SNWV with a GF Score™ of 29/100 and a GF Value™ of $12.73 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 703 Medical Devices & Instruments companies, SANUWAVE Health ranks worse than 99.29% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for SANUWAVE Health's Debt-to-Equity or its related term are showing as below:
SNWV'
s Debt-to-Equity Range Over the Past 10 Years
Min: -19.99 Med: -0.72 Max: 14.19
Current: 7.43
During the past 13 years, the highest Debt-to-Equity Ratio of SANUWAVE Health was 14.19. The lowest was -19.99. And the median was -0.72.
SNWV's Debt-to-Equity is ranked worse than 99.29% of 703
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs SNWV: 7.43
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
SANUWAVE Health Debt-to-Equity Related Terms
SANUWAVE Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for SANUWAVE Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNWV vs SRTS, COCH, ECOR: Debt-to-Equity Comparison
For the Medical Devices subindustry, SANUWAVE Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SANUWAVE Health Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SANUWAVE Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where SANUWAVE Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SANUWAVE Health (SNWV) has a Debt-to-Equity of 7.43 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SANUWAVE Health and its competitors. According to the industry distribution chart, SANUWAVE Health ranks #698 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 99.3%.
Is SANUWAVE Health's Debt-to-Equity too high?
SANUWAVE Health's current Debt-to-Equity is 7.43. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. SANUWAVE Health's value of 7.43 is 3130.4% above this industry median. Based on the distribution chart, SANUWAVE Health ranks #698 out of 703 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, SANUWAVE Health has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SANUWAVE Health's Debt-to-Equity compare to SRTS and COCH?
According to the Medical Devices & Instruments industry distribution chart, SANUWAVE Health ranks #698 out of 703 companies for Debt-to-Equity. This places SANUWAVE Health in the lower half of its industry. The industry median Debt-to-Equity is 0.23. SANUWAVE Health's value of 7.43 is 3130.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SANUWAVE Health's current Debt-to-Equity of 7.43 is 3130.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SANUWAVE Health and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SANUWAVE Health's current Debt-to-Equity is 7.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SANUWAVE Health stock overvalued right now?
Based on GuruFocus' analysis, SANUWAVE Health (SNWV) is currently considered Possible Value Trap. The stock's GF Value™ is $12.73, compared to a current price of $5.41 — trading 57.5% below its estimated fair value. The current Debt-to-Equity is 7.43 and 3130.4% above the Medical Devices & Instruments industry median of 0.23. SANUWAVE Health's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For SANUWAVE Health (SNWV), the current Debt-to-Equity is 7.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SANUWAVE Health (SNWV) Overvalued in 2026?
Based on GuruFocus' analysis, SANUWAVE Health stock appears to be undervalued.
The current stock price of $5.41 is trading 57.5% below its estimated GF Value™ of $12.73.
GuruFocus considers SANUWAVE Health to be Possible Value Trap.
Key valuation signals for SNWV:
Debt-to-Equity: 7.43
GF Value™: $12.73 vs. price of $5.41 (57.5% below fair value)
Industry Position: 3130.4% above the Medical Devices & Instruments median (#698 of 703)
No single metric tells the full story. See the SNWV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SANUWAVE Health Inc is a medical device company providing directed energy products into the wound care space. It is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. Sanuwave's patented, FDA-cleared, and commercialised product is the UltraMIST system, which is used to treat a variety of acute and chronic wounds using ultrasound technology. The company operates in one reportable segment, the design and sale of medical devices. Geographically, the company generates revenue mainly from the United States.
29GF Score
Get the complete analysis for SNWV
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNWV has been successfully added to your 
